Business
edge labs. When business decisions often force pharma to shut down a mature programme, it potentially allows interested academic researchers and small biotechs to utilise the knowledge to accelerate other related programmes and could provide future benefit to pharma. One can consid- er this much like having an independent research group working on increasing the value of an asset that was deemed to be of little value, with no cost. Surely the possibilities exist that if 20 such project accesses were granted, perhaps one would provide returns and possibly a later stage programme of significant value. A simple framework for this could be as simple as non-confidential summaries that could be put in a web-based storefront. Deals would have to be relatively simple so as to not impede development of the technology or possible future business deals – perhaps with the pharma having a time-limited first rights for negotiation down the way. While the business case for the development of certain drug leads which have undergone a signifi-
cant amount of pre-clinical and often clinical assessment may no longer be appealing to pharma; academia, foundations and non-profits may still find value and reposition or repurpose these fallen angels through their in-house programmes starved of promising candidates. This, of course, requires that pharma does not attach strings that are ardu- ous for the development path. We propose and seek an obligatory mandate by the FDA and other drug approval organisations for the promoting company to provide the unformulated drug for non-profit and academic uses.
Open science and data sharing The open science mantra has initiated some excite- ment of the possibilities of gaining a better grasp on science/data often hidden away behind locked doors, or just merely left on the lab bench to decay and rot. The concept behind open science is not new – openly share results of pre-clinical discovery in hopes that the information will enable new ideas and concepts to emerge and push drug development
33rd
International Exhibition for Fine and Speciality Chemicals
The industry’s premier sourcing and networking event
Some 400 international exhibitors off er bespoke solutions and specifi c substances to enhance
products or develop new chemical solutions.
Fine and speciality chemicals for various industries:
pharmaceuticals • agrochemicals • petrochemicals • cosmetics • adhesives & sealants • paints & coatings • polymers • biotechnology • colourants & dyestuff s • food & drink • industrial cleaning • reprography & printing • water treatment and much more.
Organisers:
20 – 21 JUNE 2018 Koelnmesse
Cologne, Germany
www.chemspeceurope.com
Drug Discovery World Spring 2018
41
Top conferences and workshops off er
valuable insights into ongoing R&D projects!
Agrochemical Lecture Theatre Chemspec Careers Clinic Pharma Lecture Theatre
Regulatory Services Lecture Theatre RSC Lecture Theatre Innovative Start-ups
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72
